+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Optimal treatment of dyslipidemia in high-risk patients: intensive statin treatment or combination therapy?

Optimal treatment of dyslipidemia in high-risk patients: intensive statin treatment or combination therapy?

Preventive Cardiology 10(1): 31-35

A recent update to the National Cholesterol Education Program's Adult Treatment Panel III guidelines suggests low-density lipoprotein cholesterol (LDL-C) goals of <70 mg/dL in very-high-risk patients and <100 mg/dL in high-risk patients. Currently available 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are not equal in their ability to lower LDL-C, and it is unlikely that the substantial LDL-C reductions that are often needed in high-risk persons can be achieved with starting doses of some of the older statins. Possible alternatives in such cases include the use of high-dose statin therapy, a more efficacious statin, or combination therapy. Recent clinical data have demonstrated a greater likelihood of coronary heart disease event reduction with aggressive statin therapy that lowers LDL-C in a robust fashion (>30%-40%) than with moderate therapy. Until data from ongoing trials of combination therapy are available, however, monotherapy with a potent statin should be initiated to lower LDL-C. Nonetheless, for residual elevation in triglycerides and/or reduced high-density lipoprotein cholesterol, adding a second agent (eg, fenofibrate, niacin) is a reasonable option.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 049810993

Download citation: RISBibTeXText

PMID: 17215631

DOI: 10.1111/j.1520-037x.2007.05662.x

Related references

Intensive statin treatment or combination therapy in high-risk patients. Preventive Cardiology 10(1): 7-8, 2007

Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis. Current Medical Research and Opinion 27(5): 1067-1078, 2011

Use of a treatment optimization algorithm involving statin-ezetimibe combination aids in achievement of guideline-based low-density lipoprotein targets in patients with dyslipidemia at high vascular risk Guideline-based Undertaking to Improve Dyslipidemia Management in Canada (GUIDANC). Canadian Journal of Cardiology 27(2): 138-145, 2011

Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. Journal of Clinical Lipidology 2(6): 426-435, 2008

Rationale for combination therapy with statin drugs in the treatment of dyslipidemia. Current Atherosclerosis Reports 7(1): 29-33, 2005

Effects of High Intensity Statin Therapy in the Treatment of Diabetic Dyslipidemia in Patients with Coronary Artery Disease. Current Pharmaceutical Design 24(4): 427-441, 2018

Rationale for intensive statin treatment in high-risk patients. Preventive Cardiology 9(2): 91-95, 2006

Niacin-ER/statin combination for the treatment of dyslipidemia: focus on low high-density lipoprotein cholesterol. Journal of Clinical Hypertension 8(7): 493-9; Quiz 500-1, 2006

Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease. American Journal of Cardiology 104(6): 798-804, 2009

Optimal management of persistent mixed dyslipidemia after statin initiation warrants combination therapy. American Journal of Cardiology 104(12): 1695-1696, 2009

Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events. American Journal of Cardiology 89(4): 390-394, 2002

Finding the optimal combination therapy for the treatment of newly diagnosed AML in older patients unfit for intensive therapy. Leukemia Research 39(2): 183-191, 2015

Safety and efficacy of statin treatment alone and in combination with fibrates in patients with dyslipidemia: a meta-analysis. Current Medical Research and Opinion 30(1): 1-10, 2014

Risk factors associated with atherogenic dyslipidemia in the presence of optimal statin therapy. International Journal of Cardiology 248: 355-360, 2017

Regression of Some High-risk Features of Age-related Macular Degeneration (AMD) in Patients Receiving Intensive Statin Treatment. Ebiomedicine 5: 198-203, 2016